Russell Investments Group Ltd. Acquires 44,979 Shares of ANI Pharmaceuticals, Inc. $ANIP

Russell Investments Group Ltd. raised its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 32.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 185,475 shares of the specialty pharmaceutical company's stock after buying an additional 44,979 shares during the period. Russell Investments Group Ltd. owned approximately 0.85% of ANI Pharmaceuticals worth $12,418,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Hohimer Wealth Management LLC increased its stake in shares of ANI Pharmaceuticals by 5.2% during the 1st quarter. Hohimer Wealth Management LLC now owns 4,989 shares of the specialty pharmaceutical company's stock worth $334,000 after purchasing an additional 247 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of ANI Pharmaceuticals by 3.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,523 shares of the specialty pharmaceutical company's stock valued at $582,000 after purchasing an additional 364 shares during the last quarter. MetLife Investment Management LLC boosted its holdings in shares of ANI Pharmaceuticals by 6.3% in the 4th quarter. MetLife Investment Management LLC now owns 11,397 shares of the specialty pharmaceutical company's stock valued at $630,000 after purchasing an additional 675 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of ANI Pharmaceuticals by 163.8% in the 1st quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock valued at $95,000 after purchasing an additional 881 shares during the last quarter. Finally, National Bank of Canada FI acquired a new position in shares of ANI Pharmaceuticals during the 1st quarter valued at $79,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ANIP has been the topic of several recent research reports. Truist Financial lifted their target price on shares of ANI Pharmaceuticals from $65.00 to $77.00 and gave the company a "hold" rating in a report on Monday, August 11th. Wall Street Zen raised shares of ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 16th. HC Wainwright reaffirmed a "buy" rating and set a $93.00 price objective (up previously from $84.00) on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Guggenheim reissued a "buy" rating and set a $86.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. Finally, Piper Sandler reissued an "overweight" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $84.75.

Insider Buying and Selling at ANI Pharmaceuticals

In related news, Director Patrick D. Walsh sold 9,000 shares of the company's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $89.05, for a total transaction of $801,450.00. Following the completion of the sale, the director directly owned 70,048 shares of the company's stock, valued at approximately $6,237,774.40. This represents a 11.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Matthew J. Leonard sold 6,937 shares of the stock in a transaction on Monday, August 18th. The shares were sold at an average price of $88.17, for a total transaction of $611,635.29. Following the completion of the sale, the director directly owned 9,392 shares of the company's stock, valued at approximately $828,092.64. This trade represents a 42.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 301,247 shares of company stock worth $26,264,427 in the last quarter. 11.10% of the stock is owned by corporate insiders.

ANI Pharmaceuticals Stock Up 0.3%

Shares of ANIP traded up $0.2750 during mid-day trading on Friday, hitting $91.4150. 116,405 shares of the company's stock were exchanged, compared to its average volume of 371,619. The firm has a fifty day moving average of $70.06 and a two-hundred day moving average of $65.69. ANI Pharmaceuticals, Inc. has a twelve month low of $52.50 and a twelve month high of $92.53. The stock has a market cap of $1.98 billion, a price-to-earnings ratio of -118.83 and a beta of 0.61. The company has a quick ratio of 1.96, a current ratio of 2.54 and a debt-to-equity ratio of 1.39.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its quarterly earnings data on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.38. The business had revenue of $211.37 million during the quarter, compared to the consensus estimate of $187.18 million. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. ANI Pharmaceuticals's quarterly revenue was up 53.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.02 EPS. On average, sell-side analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.